What is MS Phase 2 Study ACT-128800?
Category: Others
See also: Clinical Trial
NCT01006265 is a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of 3 doses of ACT-128800 administered for 24 weeks in patients with relapsing-remitting multiple sclerosis. Other study name is AC-058B201.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Cognitive confusion | 1 | 0 | |
| Participate in clinical trial | 1 | 0 | |
| Walking problems | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Last updated: